Market Overview

UPDATE: J.P. Morgan Reiterates on Medtronic Following Solid 2Q Results


In a report published Wednesday, J.P. Morgan analyst Michael Weinstein reiterated a Neutral rating on Medtronic (NYSE: MDT), and raised the price target from $59.00 to $63.00.

In the report, J.P. Morgan noted, “Medtronic reported solid 2Q results Tuesday, as revenues of $4.194B (+2.4%, +3.3% cc) came in $18M above Street consensus. Sales were buoyed by a strong performance from CRM and Diabetes, offset by weakness in Spine, Neuromodulation, and Endovascular. Organic sales growth was 3.1% in the quarter, basically unchanged from the 3.2% growth Medtronic posted in 1Q but below the average of 4.1% in FY13. On the bottom line, the company reported adjusted EPS of $0.91 (+3.7%), a penny above consensus. Following these results, we are adjusting our estimates for FY14 and beyond.”

Medtronic closed on Tuesday at $57.94.

Latest Ratings for MDT

Sep 2020Truist SecuritiesMaintainsBuy
Sep 2020Wolfe ResearchInitiates Coverage OnPeer Perform
Aug 2020Credit SuisseMaintainsOutperform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!

Posted-In: J.P. Morgan Michael WeinsteinAnalyst Color Price Target Analyst Ratings

Latest Ratings

CTASRBC CapitalMaintains360.0
MDTTruist SecuritiesMaintains120.0
ATEMaxim GroupInitiates Coverage On1.0
MNPRMaxim GroupInitiates Coverage On11.0
RDS/BScotiaBankInitiates Coverage On34.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at